Company Overview and News

0
Port Kembla shut due to cargo ship blaze

2018-06-18 theage.com.au
Shipping at Port Kembla, the second-largest coal export port in NSW, was suspended on Monday after a cargo ship docked there caught fire.
BSL BLSFY BLSFF

0
Port Kembla shut due to cargo ship blaze

2018-06-18 smh.com.au
Shipping at Port Kembla, the second-largest coal export port in NSW, was suspended on Monday after a cargo ship docked there caught fire.
BSL BLSFY BLSFF

9
Australia's Strong Q1 Growth: ETFs in Focus

2018-06-11 zacks
The Australian economy remained strong in the first quarter of 2018 with GDP growth of 3.1% compared to 2.4% in the last quarter of 2017. The reported growth was above expectations of 2.8% expansion and marked the quickest annual growth rate since second-quarter 2016.
MQBKY WBC BSL TAH CHJHF CHA WEBNF MCQEF WBK WHC TABCF WBC BLSFY BLSFF 0728 MQG TACBY

16
G7 the next chance to head off possible global trade 'implosion'

2018-06-07 abc.net.au
Leaders of the world's biggest advanced economies will meet in Canada this weekend, for a G7 summit like no other.
RTPPF RIO BSL RIO BLSFY RIO BLSFF RTNTF

0
Strikes to impact on major infrastructure projects

2018-06-05 theage.com.au
Work on major NSW infrastructure projects including power stations, steelworks, light rail, national defence and a new jail will be affected as hundreds of specialist trade workers go on strike for three days from Wednesday.
BSL BLSFY BLSFF

0
Strikes to impact on major infrastructure projects

2018-06-05 smh.com.au
Work on major NSW infrastructure projects including power stations, steelworks, light rail, national defence and a new jail will be affected as hundreds of specialist trade workers go on strike for three days from Wednesday.
BSL BLSFY BLSFF

0
BlueScope hikes guidance on strong US performance

2018-05-15 theage.com.au
Steel maker BlueScope Steel has raised its guidance for underlying earnings before interest and tax (EBIT) for the second half by 12.2 per cent, helped by stronger margins at a facility in the United States.
BSL BLSFY BLSFF

0
BlueScope hikes guidance on strong US performance

2018-05-15 smh.com.au
Steel maker BlueScope Steel has raised its guidance for underlying earnings before interest and tax (EBIT) for the second half by 12.2 per cent, helped by stronger margins at a facility in the United States.
BSL BLSFY BLSFF

0
Australia's BlueScope hikes H2 underlying EBIT guidance on strong U.S. performance

2018-05-14 reuters
May 15 (Reuters) - Australian steel maker BlueScope Steel Ltd on Tuesday raised its guidance for underlying earnings before interest and tax (EBIT) for the second half by 12.2 percent, helped by stronger margins at a facility in the United States.
BSL BLSFY BLSFF

0
UPDATE 1-Australia's BlueScope hikes H2 underlying EBIT guidance on strong U.S. performance

2018-05-14 reuters
(Reuters) - Australian steel maker BlueScope Steel Ltd on Tuesday raised its guidance for underlying earnings before interest and tax (EBIT) for the second half by 12.2 percent, helped by stronger margins at a facility in the United States.
BSL BLSFY BLSFF

0
Government denies political concerns behind choice not to tax Chinese steel imports

2018-05-09 nzherald.co.nz
The government says political considerations about New Zealand's relationship with China aren't the reason why it chose not to tax Chinese steel imports, as local steel producer New Zealand Steel attempts to have that decision overturned in the High Court.
BSL BLSFY BLSFF

0
NZ Steel wants High court to overturn decision not to tax imports from China

2018-05-07 nzherald.co.nz
New Zealand Steel wants the High Court to overturn a decision by the government not to tax Chinese steel imports, which the firm says flooded the local market and cut into profits.
BSL BLSFY BLSFF

0
Trump delays metal tariffs on Canada, EU, Mexico, exempts some others

2018-05-01 reuters
WASHINGTON (Reuters) - U.S. President Donald Trump has postponed the imposition of steel and aluminum tariffs on Canada, the European Union and Mexico until June 1, and has reached agreements for permanent exemptions for Argentina, Australia and Brazil, the White House said on Monday.
BSL BLSFY BLSFF

0
'Stark data': How postcodes are shaping the destiny of young Australians

2018-03-25 theage.com.au
Youth unemployment has skyrocketed by more than 10 per cent in two years in some regions, as a new national report reveals how postcodes shape the future of young Australians.
BSL BLSFY BLSFF

0
'Stark data': How postcodes are shaping the destiny of young Australians

2018-03-25 smh.com.au
Youth unemployment has skyrocketed by more than 10 per cent in two years in some regions, as a new national report reveals how postcodes shape the future of young Australians.
BSL BLSFY BLSFF

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...